Male Hypogonadism Market Report Provides Point To Point Information of the Market Capacity, Production, Market Share, Revenue and Growth Rate

By 2022, the Male Hypogonadism Market is estimated to reach $ 323 million by 2022 and is expected to grow at a CAGR of 3.1% from 2016 to 2022. The pituitary disease sector accounts for nearly half of the total market share in 2015 and is expected to remain dominant over the analysis period.

Hypogonadism in the male is a clinical condition in which the testes fail to produce sufficient testosterone, resulting in decreased development of muscle mass, loss of body hair growth, development of breast tissue and a lack of vocalization. Growth in the male hypogonadism market is due to increased prevalence and frequency of patients with testosterone deficiency, increased rates of infertility, and increased patient awareness of options for treating STDs according to certain campaigns conducted by governments. In addition, the risk of germs is very high in the elderly population and in obese and diabetic populations.

The increase in the elderly population and the occurrence of chronic lifestyle disorders (obesity and diabetes) are expected to further stimulate market growth. However, the high side effects of all testosterone products are expected to hamper the growth of the testosterone replacement therapy (TRT) segment in this market. Technology advancement is expected to provide new opportunities during the forecast period.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/1874?utm_source=sy

Major players operating in this market include
• AbbVie Inc.
• Allergan plc
• AstraZeneca plc
• Bayer AG
• Eli Lilly and Company Ltd.
• Endo International plc
• Merck & Co. Inc.
• Ferring Holding S.A.
• Finox Biotech
• IBSA Institut Biochimque SA
• Laboratoires Genevrier
• Teva Pharmaceutical Industries Ltd.

North America accounted for majority of the share (more than three-fourths) in the market in 2015, and is expected to remain dominant throughout the forecast period. This is due to growth in population suffering from primary and secondary causes of hypogonadism, and increased patient awareness about the availability of treatment options.

In addition, high adoption rate of technologically advanced products and presence of highly sophisticated healthcare infrastructure are anticipated to create new growth opportunities for key players in this market. Europe was the second leading market in 2015. However, Asia-Pacific is expected to be register the highest CAGR of 7.2% throughout the analysis period, owing to rise in hypogonadism patient population along with increase in adoption of western lifestyle, unhealthy diet habits, and growth in urbanization.

Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/1874?utm_source=sy

Key Findings of The Male Hypogonadism Market
• By drug therapy, gonadotropin and gonadotropin-releasing hormones therapy segment is projected to grow at the highest CAGR of 8.9% during the forecast period.
• Pituitary disorders segment is expected to grow at the CAGR of 3.2%.
• Injectables accounted for nearly half of the market share in 2015.
• North America accounted for majority of the share (more than three-fourths) in 2015, and is expected to remain dominant throughout the forecast period.
• U.S. accounted for the majority share in the North American market in 2015, and the Mexican market is expected to grow at the highest CAGR of 6.7%.
Key players have adopted product approval as their key strategy to cater to the changing needs of the industry. There is high competition among key players to launch innovative, technologically advanced products to increase their market share and serve the patients in a better way.

Access Full Summery @ https://www.alliedmarketresearch.com/male-hypogonadism-market?utm_source=sy

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:

David Correa

5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States

Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975

help@alliedmarketresearch.com

This release was published on openPR.